Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pulse Biosciences (PLSE) Cash from Financing Activities (2020 - 2025)

Pulse Biosciences (PLSE) has 6 years of Cash from Financing Activities data on record, last reported at $381000.0 in Q4 2025.

  • For Q4 2025, Cash from Financing Activities fell 99.21% year-over-year to $381000.0; the TTM value through Dec 2025 reached $17.2 million, down 84.43%, while the annual FY2025 figure was $17.2 million, 84.43% down from the prior year.
  • Cash from Financing Activities reached $381000.0 in Q4 2025 per PLSE's latest filing, down from $2.0 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $65.1 million in Q3 2022 and bottomed at -$549000.0 in Q4 2021.
  • Average Cash from Financing Activities over 5 years is $15.1 million, with a median of $2.1 million recorded in 2023.
  • Peak YoY movement for Cash from Financing Activities: surged 19278.03% in 2021, then plummeted 564.62% in 2023.
  • A 5-year view of Cash from Financing Activities shows it stood at -$549000.0 in 2021, then skyrocketed by 96.9% to -$17000.0 in 2022, then surged by 4829.41% to $804000.0 in 2023, then soared by 5895.27% to $48.2 million in 2024, then plummeted by 99.21% to $381000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Financing Activities were $381000.0 in Q4 2025, $2.0 million in Q3 2025, and $14.8 million in Q1 2025.